Clanza

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clanza

Property Description
Active ingredient Aceclofenac
Form Oral tablet (Systemic)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic compound (Phenylacetic acid derivative)

Clanza: Identity and Pharmacological Classification

The medicine known by the trade name Clanza is a prescription-only pharmaceutical preparation whose active ingredient is Aceclofenac. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a compound group recognized globally for its anti-inflammatory and pain-relieving capabilities. This substance is a synthetic derivative chemically belonging to the phenylacetic acid group, defining its functional relationship within the category of anti-rheumatic agents.

The core identity of Aceclofenac is established by its primary biological role as a Cyclooxygenase (COX) inhibitor. This mechanism is clinically recognized for its ability to mitigate symptoms related to pain, swelling, and inflammation, providing systemic anti-inflammatory properties.

Composition, Form, and General Therapeutic Role

The active ingredient, Aceclofenac, is typically delivered as a single active substance product formulated into an oral tablet, intended for systemic action throughout the body upon ingestion. This composition ensures that the full therapeutic effect is delivered exclusively by the Aceclofenac molecule.

The purpose of this systemic delivery is to achieve the general therapeutic objective of symptomatic relief. Aceclofenac is designed to utilize its combined analgesic, anti-inflammatory, and antipyretic effects to reduce discomfort and alleviate the inflammatory component of various conditions. This function includes the reduction of pain and inflammation associated with musculoskeletal conditions, establishing the drug’s role as a therapeutic tool for managing widespread inflammation.

What side effects are possible with Clanza?

Possible Side Effects and Safety Information

The official safety profile of Clanza (Aceclofenac) is classified by regulatory authorities, with potential effects grouped by frequency and the body system affected. The core safety considerations are related to the characteristics common to Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Adverse Reaction Scope

Classification Examples of Listed Effects
Common (1 to 10 in 100) Dizziness, dyspepsia, nausea, abdominal pain, diarrhea, and increased liver enzymes.
Uncommon (1 to 10 in 1,000) Flatulence, gastritis, constipation, vomiting, rash, pruritus (itching), and edema (swelling).
Rare (1 to 10 in 10,000) Anemia, hypersensitivity reactions, and visual disturbances.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions that have been reported, including gastrointestinal bleeding, ulceration, or perforation, and severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Additionally, the medicine may be associated with an increased risk of thromboembolic events, such as myocardial infarction (heart attack) or stroke.

Population and Exposure Notes

  • Dose- or Exposure-Related Patterns: The official label states that the risk of both gastrointestinal complications and thrombotic events may increase with higher doses and longer duration of use.
  • Population-Specific Safety: Older adults are documented to have an increased risk of adverse reactions, particularly serious gastrointestinal events. The medicine is contraindicated (should not be used) in patients with severe heart failure, renal impairment, or hepatic impairment, or those with active gastrointestinal bleeding or ulceration.

This structure ensures that the safety information is presented according to the formal classifications and explicit limitations defined in government regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section outlines the officially documented overdose manifestations and required emergency procedures for Aceclofenac (Clanza) as defined by government regulatory authorities.

Documented Manifestations and Severe Outcomes

Symptoms following an overdose are documented to affect the nervous system and gastrointestinal tract. Clinical manifestations may include nausea, vomiting, epigastric pain, headache, drowsiness, and dizziness. More serious neurological signs may occasionally present as convulsions or lead to coma and respiratory depression.

Severe poisoning has been officially associated with the risk of major organ damage, including acute renal failure and liver damage.

Required Emergency Actions and Monitoring

In the event of a potentially toxic or life-threatening overdose, immediate medical attention is required to implement time-sensitive procedures:

  • Activated charcoal should be considered within one hour of ingesting a potentially toxic amount.
  • Gastric lavage should be considered within one hour for a potentially life-threatening overdose in adults.
  • Treatment is primarily symptomatic and supportive, focusing on complications such as hypotension and convulsions.

Following exposure, patients should be observed for at least four hours, with renal and liver function requiring close monitoring due to the documented risk of organ toxicity. Regulatory documents note that specific procedures like dialysis are likely to be ineffective.

Therapeutic Uses of Clanza

Aceclofenac (Clanza) is commonly used to help with symptomatic relief across several major domains of pain and inflammation, and may assist with maintaining functional stability. It is considered relevant for easing symptoms that are linked to inflammatory or irritative states.

The medication is applied across domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is used for managing symptom clusters that may become intense or disruptive, including joint pain, swelling, and functional stiffness. It provides support that helps ease the overall symptom burden and may contribute to improved comfort during periods of heightened symptoms.

Common Therapeutic Scenarios

Clanza plays a role in managing symptoms of inflammatory joint conditions and is relevant for easing discomfort in acute musculoskeletal settings, including low back pain flare-ups, extraarticular rheumatism, and pain associated with trauma or dental procedures. It is applied in scenarios where additional management of discomfort is required, providing symptomatic relief that may help patients cope more steadily when symptoms interfere with routine activities.

Quick Fact: Relief for Pain and Inflammation
Supports relief from symptoms related to physical discomfort, swelling, and stiffness in conditions involving inflammatory processes.

Eligibility and Restrictions for Use

Eligibility for Clanza (Aceclofenac)

Clanza is officially indicated for use in adults to manage specific painful and inflammatory conditions. Eligibility is strictly limited by regulatory authorities based on certain health conditions and patient populations.

Contraindicated Populations (Must Not Use)
Hypersensitivity to Aceclofenac, Aspirin, or any other NSAID.
Severe organ failure: Severe hepatic failure or severe renal failure.
Cardiovascular disease: Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, or cerebrovascular disease.
Gastrointestinal risks: Active or recurrent peptic ulcer/haemorrhage, or a history of GI bleeding/perforation related to prior NSAID use.
Active bleeding or bleeding diathesis.
Pregnancy during the third trimester.

Age and Condition-Based Restrictions

  • Pediatric Use: Clanza is not recommended for use in children or adolescents under 18 years of age due to a lack of clinical data.
  • Elderly Patients: The elderly may use the medicine but are at increased risk of serious adverse reactions, necessitating the use of the lowest effective dose for the shortest duration.
  • Mild to Moderate Impairment: Patients with mild-to-moderate renal or hepatic impairment may be permitted use, but require close medical surveillance.
  • Reproductive Status: The medicine is not recommended for women who are attempting to conceive or who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aceclofenac is structured around documented risks that lead to specific co-administration restrictions, altered drug exposure, and reduced therapeutic efficacy of co-administered medicines.

A primary restriction, consistently stated in regulatory documents, is the requirement to avoid simultaneous use with other NSAIDs, including COX-2 selective inhibitors and high-dose Aspirin, due to the officially documented additive risk of adverse effects, specifically gastrointestinal bleeding and ulceration.

Pharmacokinetic risks involve the potential for Aceclofenac to increase plasma levels of certain medicines by reducing their renal elimination. Regulatory information indicates this effect for substances such as Lithium and Digoxin. Co-administration with Methotrexate may similarly increase its concentration, leading to an officially documented risk of increased toxicity.

Pharmacodynamic interactions are also described in labeling. Co-administration with Anticoagulants (e.g., Warfarin) is documented to enhance the anticoagulant effect, which results in an increased risk of hemorrhage. Furthermore, Aceclofenac may reduce the therapeutic efficacy of both Diuretics and Anti-hypertensives (ACE-inhibitors and ARBs).

Timing-based rules apply to certain combinations: Aceclofenac must not be used for 8 to 12 days following administration of Mifepristone. Finally, interaction risks with ACE-inhibitors or ARBs are noted to be heightened in the elderly and in dehydrated patients, and close medical surveillance is warranted for regular alcohol consumers due to the officially stated risk of gastric bleeding.

Mechanism of Action

The mechanism of Aceclofenac is primarily defined by its competitive inhibition of the Cyclooxygenase ( COX) enzymes, mainly the inducible COX-2 isoform. This molecular interaction halts the Arachidonic Acid Cascade, thereby suppressing the cellular synthesis of prostaglandins ( PGE2).

The consequence of reduced PGE2 levels manifests as a dual system-level modulation. Peripherally, the suppression of prostaglandin production affects the sensitivity of nociceptors. Centrally, the mechanism influences the hypothalamic temperature set point.

Additionally, the drug exhibits secondary modulation, including inhibition of inflammatory cytokines such as IL-1beta and TNF-alpha via the NF-kappa B pathway. The mechanism also involves inhibition of the constitutive COX-1 enzyme, which results in a reduction of homeostatic prostaglandins. The action is confined to the modulation of chemical mediators; it does not influence the structural repair of established tissue components.

Dosage and Administration Information

Aceclofenac, the active substance in Clanza, is designed for oral administration as a systemic therapy. Dosing options include the 100 mg immediate-release tablet and the 200 mg controlled-release tablet. The maximum total daily intake for any adult regimen is 200 mg.

The standard use pattern involves administering the 100 mg tablet twice daily, typically once in the morning and once in the evening, while the 200 mg tablet is taken once daily. To ensure proper administration, tablets must be swallowed whole with liquid and should not be crushed or chewed. Intake is structured to occur with or after food.

Usage Parameters and Adjustments

The overall treatment duration is guided by the principle of using the lowest effective dose for the shortest duration necessary for symptom control. Use is not recommended for patients under 18 years due to insufficient clinical data. A critical adjustment applies to patients with hepatic impairment, where the initial daily dose is reduced to 100 mg. No equivalent modification is required for mild renal impairment or older adults, although the standard lowest dose principle applies to these groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clanza (aceclofenac) is a non-steroidal anti-inflammatory drug (NSAID). Research has examined the drug's activity, which is primarily achieved through the inhibition of the cyclo-oxygenase (COX) enzyme.


Primary Efficacy Studies

Multiple randomized, controlled clinical trials (RCTs), including Phase III studies, have been conducted to evaluate the effects of Clanza in patients with chronic inflammatory and painful conditions, such as osteoarthritis (OA) and rheumatoid arthritis (RA). These studies typically reported on changes in disease activity scores, pain levels (often using a Visual Analogue Scale, or VAS), and functional capacity scores.

  • Study Design: Primary studies compared the drug's outcomes to a placebo or to other established NSAIDs over periods ranging from 12 weeks to an extended duration.
  • Key Findings: Research reported significant changes in pain relief and functional improvement in patients with chronic low back pain (CLBP), OA, and RA. In comparative studies, Clanza's outcomes were found to be similar to those reported for common comparators.

Pharmacokinetic and Long-term Data

  • Formulation Equivalence: Studies assessed the pharmacokinetics of a controlled-release (CR) formulation of Clanza (200 mg once daily) and reported its bioequivalence to the immediate-release formulation (100 mg twice daily). This research also assessed the effect of co-administration with food on drug absorption levels.
  • Long-term Observation: Follow-up studies, including open-label extensions, have examined outcomes in participants over an extended duration, with data collected on long-term changes in symptom levels and overall safety data points. Data from patients over 75 years old primarily focused on the collection of these safety data points.

Frequently Asked Questions (FAQ)

Common questions about Clanza (FAQ)


Q: Is it safe to drink alcohol while using Clanza?

A: Official regulatory warnings advise that consuming alcohol regularly may increase the risk of gastrointestinal side effects, such as gastric bleeding. The need for close medical surveillance is noted for regular alcohol consumers.

Q: Can I take Clanza if I have kidney problems?

A: The medicine is contraindicated, meaning it should not be used, in patients with severe renal failure (severe kidney problems). Patients with mild-to-moderate renal impairment are noted as a population where close medical surveillance is required if the medicine is used.

Q: Is Clanza known to cause issues with liver function?

A: Severe hepatic failure (severe liver problems) is a contraindication for use. Official regulatory documents list increased liver enzymes as a common side effect, and monitoring of liver function is noted as being required during long-term treatment.

Q: What is the mechanism of action of Clanza?

A: Official documents describe the drug's primary action as inhibiting the Cyclooxygenase (COX) enzyme. This molecular interaction works to suppress the body's synthesis of prostaglandins, which are chemicals associated with pain and swelling.

Q: Can Clanza be crushed or split?

A: No. The official product information states that the tablets are formulated for oral administration and must be swallowed whole with liquid. They should not be crushed or chewed, consistent with the formulation requirements.

Q: Does Clanza have a 'Black Box' warning?

A: Official regulatory documents, including those from the FDA, require highlighting the serious potential for an increased risk of arterial thrombotic events (such as heart attack or stroke) and serious gastrointestinal events (like bleeding or ulceration). These risks are typically associated with higher doses and longer durations of use.

Q: How long do you need to take Clanza?

A: Treatment is guided by the principle of using the lowest effective dose for the shortest duration necessary to control symptoms. The appropriate duration is typically determined by a clinician for the specific condition.

Q: Can Clanza cause changes in sleep patterns?

A: Regulatory documents list central nervous system effects such as dizziness or drowsiness as common side effects.

Q: Is Clanza available over the counter?

A: According to the official classification profile, Clanza is designated as a prescription-only medicine.

Q: What happens if I miss taking Clanza?

A: Official regulatory information describes that a missed dose is taken as soon as it is remembered, unless the next scheduled dose is nearly due. A double dose should not be taken.

Q: Are there any long-term side effects reported for Clanza?

A: The official label notes that the risk of both gastrointestinal complications and thrombotic events may increase with longer duration of use. Monitoring of liver and renal function and blood counts is noted as being required during long-term treatment.

Q: Are there generic versions of Clanza available?

A: The active ingredient in Clanza is Aceclofenac, which is the official generic name of the substance. Generic versions of medicines containing this active ingredient are available internationally.

Q: Can I stop taking Clanza suddenly?

A: Regulatory documents state that if the medicine is discontinued, the symptoms for which it was taken may return.

Q: Is it true that Clanza can cause dizziness?

A: Yes, dizziness is listed in regulatory documents as a common side effect of the medicine.

Q: How long after stopping Clanza does it stay in the system?

A: The mean elimination half-life of the active ingredient, Aceclofenac, is approximately 4 hours. The half-life describes the time it takes for half of the drug to be eliminated from the body.

Q: What if I accidentally take more Clanza than intended?

A: Symptoms of overdose are described in official documents and may include headache, nausea, vomiting, epigastric pain, or gastrointestinal irritation. In the case of overdose, the official documents note that treatment involves supportive and symptomatic care.

Q: Are there any specific safety precautions for women taking Clanza?

A: The medicine is not recommended for women who are attempting to conceive, as its use may impair female fertility. It is also contraindicated (should not be used) during the third trimester of pregnancy.

Q: Is Clanza used for mental health conditions?

A: No. The medicine is officially indicated for the symptomatic relief of pain and inflammation in physical conditions, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Q: Are there warnings about driving or operating machinery while on Clanza?

A: No specific studies on the ability to drive have been performed for this medicine. However, caution related to driving or operating heavy machinery is noted due to the potential for common side effects like dizziness or visual disturbances.

Q: Does taking Clanza affect my immune system?

A: The mechanism of the drug involves influencing the body's inflammatory response by inhibiting the synthesis of prostaglandins and certain inflammatory cytokines. Cytokines are chemical messengers involved in the inflammatory process.

Q: Does Clanza help with inflammation?

A: Yes, the therapeutic indications state that one of the primary purposes of the drug is the symptomatic relief of inflammation and pain.

Q: What does the research say about long-term use of Clanza?

A: Follow-up and extended observation studies provided data used to inform the official warning that the risk of serious adverse effects may increase with the duration of use.

Q: Can I take other prescription medications with Clanza?

A: The regulatory profile documents known interactions with several drug classes, including anticoagulants, diuretics, anti-hypertensives (ACE-inhibitors/ARBs), and lithium, which can result in enhanced risk or reduced therapeutic effectiveness.

How should Clanza be stored and disposed of?

How to Store and Dispose of Clanza?

Clanza (Aceclofenac) must be stored and handled according to the specific conditions defined in the official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store below 30 C.
Protection Protect from light and moisture.
Packaging Keep in the original package, with the blister in the outer carton.
Child Safety Keep out of the sight and reach of children.
Stability Do not use after the expiry date (EXP) stated on the packaging.

Disposal Instructions

Unused or expired Clanza must be managed in accordance with local requirements. It is explicitly stated that this medicine must not be thrown away via wastewater or household waste to prevent environmental contamination. Consult a pharmacist or local waste authority for proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clanza found in:

A-Z Index: